Fundraising Foxオンコリスバイオファーマ株式会社
1 known investors
Find your way into オンコリスバイオファーマ株式会社
Sign up to see every warm intro you have to オンコリスバイオファーマ株式会社
- Paths you didn't know you had: your email and LinkedIn already hold routes to the オンコリスバイオファーマ株式会社 team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Oncolys develops viral therapy drugs and treatments for cancer and severe viral infections, with a focus on oncolytic viruses and rare diseases. The company operates a hybrid business model combining licensing partnerships with pharmaceutical firms and direct commercialization of its own therapies.
Founders & leadership
浦
浦田泰生Representative Director and President
Investors · 1
Frequently asked questions
- What does オンコリスバイオファーマ株式会社 do?
- Oncolys develops viral therapy drugs and treatments for cancer and severe viral infections, with a focus on oncolytic viruses and rare diseases. The company operates a hybrid business model combining licensing partnerships with pharmaceutical firms and direct commercialization of its own therapies.
- Who founded オンコリスバイオファーマ株式会社?
- オンコリスバイオファーマ株式会社 was founded by 浦田泰生.
- Who are オンコリスバイオファーマ株式会社's investors?
- オンコリスバイオファーマ株式会社's investors include Nippon Venture Capital.